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Heterozygous loss of relatively large chromosomal regions is a hallmark of the inactivation of tumour suppressor genes. Searching for
deletions in cancer genomes therefore provides an attractive option to identify new tumour suppressor genes. Here, we have
performed a genome-wide survey for regions exhibiting allelic loss in 24 commercially available breast cancer cell lines and four breast
cancer xenografts, using microsatellite analysis. The assembled allelotype revealed an average fractional allelic loss of 0.34. A total of 19
arms had low allelic loss frequencies (o25%) and 17 arms had moderate allelic loss frequencies (25–50%). Five chromosomal arms
were deleted in more than half of the breast cancer samples (8p, 10q, 13q, 17p, and 17q). Three of these frequently lost chromosomal
arms had not been identified as such by comparative genome hybridisation, illustrating the higher sensitivity of microsatellite analysis for
the detection of allelic losses. As we present allelic loss data of individual samples, our allelotype should not only aid the identification of
new breast cancer genes but also provides a baseline for myriad studies involving these breast cancer cell lines.
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Genetic analyses of sporadic breast cancers have thus far identified
few archetypal tumour suppressor genes involved in the develop-
ment of these tumours. The p53 tumour suppressor gene was
found to be mutated in 20–40% of breast cancers, and the RB1 and
E-cadherin genes were inactivated in 10–20% of tumours (Lee et al,
1988; T’Ang et al, 1988; Hollstein et al, 1991; Berns et al, 1995,
2000; Berx et al, 1995, 1996; van de Wetering et al, 2001). Other
tumour suppressor genes were mutated in only a minority of
sporadic breast cancers (o10%); that is, APC, ATM, BRCA1,
BRCA2, MAP2K4, PTEN, p16, SMAD4, VHL, and the mismatch
repair genes MLH1, MSH2, and MSH6.
The biallelic inactivation of tumour suppressor genes generally
involves a small intragenic alteration in one copy of the gene,
combined with the loss of a larger chromosomal region containing
the other allele. Although the smaller mutations may present
problems in detection, the larger regions of deletion are readily
identifiable by genomic screening. An allelotype is a genome-wide
survey for regions that are characteristically deleted in a tumour type
(Vogelstein et al, 1989). Such identified regions of frequent allelic
loss are thought to be indicative of the location of tumour suppressor
genes. Here, we present an allelotype of 24 commercially available
breast cancer cell lines and four breast cancer xenografts.
MATERIALS AND METHODS
Samples
The 28 human breast cancer samples used in this study are listed
in Figure 1. All 24 breast cancer cell lines were obtained from
American Type Culture Condition and were grown according to
their recommendations. The four breast cancer xenografts were
generated by implantation of breast cancer specimens into
immune-deficient mice, as described (Sakakibara et al, 1996).
Family history of breast cancer or BRCA1 and BRCA2 mutational
status are not known for any of the breast cancer samples. Controls
(n¼25) were non-neoplastic blood or tissue samples from
randomly selected, apparently healthy Dutch individuals. Genomic
DNA was extracted using the Qiagen DNeasy kit. Microsatellite
analyses indicated that all samples were unique and monoclonal.
Of the 28 breast cancer samples, 22 (79%) were shown to be
heterozygous for X-chromosome microsatellites (Figure 1). Y-
chromosome microsatellite DYS200 was detected in all male-
derived controls, but not in any of the breast cancer samples nor in
the female-derived controls.
Microsatellite analysis
Microsatellites were PCR-amplified as previously described (van
de Wetering et al, 2001). PCR products were separated by
electrophoresis in standard denaturing sequencing gels and the
reactions were visualised by autoradiography. All reactions were
scored by at least two investigators who were unaware of each
other’s scores. When the scores were discordant, data were re-
evaluated and reactions were repeated when desired. Primer
sequences are available upon request.
RESULTS AND DISCUSSION
We analysed 24 commercially available breast cancer cell lines and
four breast cancer xenografts for allelic losses at all 41 non-
acrocentric chromosomal arms, by PCR amplification of micro-
satellites. A single locus was analysed for each chromosomal arm,
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sencompassing a known tumour suppressor gene at 5q21 (APC),
9p21 (p16), 10q23 (PTEN), 13q12 (BRCA2), 16p13 (AXIN1), 16q22
(E-cadherin), 17p13 (p53), 17q21 (BRCA1), 18q21 (SMAD4), 19p13
(STK11), and 22q11 (hSNF5). Since constitutional non-neoplastic
tissues were not available for any of the breast cancer samples,
allelic losses were presumed based on statistical arguments.
Multiple microsatellite markers were therefore designed within a
5-centiMorgan locus, thus reducing the odds of a deletion
breakpoint between markers within a locus. Analysis of genomic
DNA from 25 randomly selected non-neoplastic control samples
revealed heterozygosity ratios for all microsatellite markers.
Heterozygosity ratios generally were about 0.1 lower than those
reported in the NCBI database, but higher ratios were also
observed. The number of microsatellites that was analysed for each
locus was such that the probability for a heterozygous sample to
have a single allele size for each of the microsatellites within the
locus was less than 5%, based on the heterozygosity ratios of the
used markers. Allelic loss of a chromosomal locus was presumed
when a breast cancer sample had a homozygous allele pattern for
all microsatellites within the locus (with Po0.05 for each locus). In
total, 146 microsatellites were analysed, resulting in an average of
3.6 markers per locus and an average P-value of 0.01. A
homozygous allele pattern was observed for the heterozygous
control samples at eight of 986 (1%) analysed loci, thus validating
the statistical approach and implying an overall error rate for the
complete allelotype of about 1%.
The presumptive allelic losses of all 28 breast cancer samples are
detailed in Figure 1. The fractional allelic loss (FAL; i.e., the
fraction of chromosomal arms that are lost in a particular sample
(Vogelstein et al, 1989)) ranged from 0.02 for xenograft BX5-1 to
0.68 for cell line BT20 (one and 28 of a total of 41 arms,
respectively). The average FAL among all 28 breast cancer samples
was 0.34, with an apparently normal distribution pattern of FAL
values. This distribution pattern is in contrast to that seen for
colorectal cancer, for example, where tumours with the micro-
satellite instability (MIN) phenotype had distinctly lower FAL
values than tumours with the chromosome instability (CIN)
phenotype (Lengauer et al, 1998). Analysis of the 28 breast cancer
samples from our cohort with markers diagnostic for the MIN
phenotype (BAT25, BAT26, and BAT40) revealed two breast cancer
samples each with an instable length of only the BAT40 marker
(i.e., MDA-MB-157 and MDA-MB-175VII), whereas the remaining
samples all had stable lengths of all three BAT markers. The
exclusive CIN phenotype among the 28 breast cancer samples from
our cohort is likely reflected in the relatively high average FAL of
0.34 among these samples (Lengauer et al, 1998; Orr-Weaver and
Weinberg, 1998; Loeb, 2001).
A compilation of the presumptive allelic losses of the
28 breast cancer samples is shown in Figure 2. Low allelic
loss frequencies (p25% of the samples) were seen at 19
chromosomal arms and 17 chromosomal arms had moderately
frequent allelic losses (25–50% of the samples). Five chromosomal
arms were lost in more than half of the samples (8p, 10q, 13q, 17p,
and 17q). It should be noted that our allelic loss frequencies are
conservative estimates of the true extent of allelic losses, as all
subchromosomal deletions not involving the analysed locus would
go undetected.
Several breast cancer allelotypes have been reported (Kerangue-
ven et al, 1997; Mertens et al, 1997; Davidson et al, 2000; Forozan
et al, 2000; Kytola et al, 2000; Osborne and Hamshere, 2000). In
general, frequencies of allelic loss reported in the literature are
lower than the frequencies identified in our cohort of breast cancer
samples. Discrepancies in allelic loss frequencies may have three,
not mutually exclusive, reasons. First, allelic losses could result
from genetic instability due to selective pressures during ex vivo
propagation of the breast cancer cells, either in cell culture or as
1p 1q 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q 7p 7q 8p 8q 9p 9q 10p10q11p11q 12p12q
BT20 + ++ ++ ++ + +++ + + +
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MDA-MB-157 + +++ ++ ++ + ++ + ++
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MDA-MB- 436 + ++ ++ + ++ ++ ++ +
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MDA-MB- 468 + ++ ++ + ++ ++ ++
SK-BR- 3 ++ + + + +
T47D ++ + + + ++ + + ++
UACC812 ++ + + +
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++ + 0.12 40 47 C
+ +++ ++ + + + 0.56 47 44 B
++ 0.12 60 56 B
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Figure 1 Presumptive allelic losses of human breast cancer samples. In all 24 ATCC breast cancer cell lines and four xenografts (with BX-identifiers) are
listed on the left and 41 non-acrocentric chromosomal arms are listed on the top. White squares: both alleles had been retained; black squares: allelic loss
was presumed; FAL: fractional allelic loss; passage no.: number of passages that the tumour cells had been propagated in vitro or in vivo, where x indicates an
unknown number of passages that the cells had undergone prior to culture in our laboratory; age: age of the patients at breast cancer diagnosis or resection
of the tumour cells, followed by their ethnicity where "C" and "B" indicate Caucasian and Black, respectively.
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sxenograft. Deletions of genetic material could occur at any time
during propagation of the tumour cells or be most pronounced
early in establishing the cell lines or xenografts. In our cohort of
breast cancer cell lines, FAL values did not correlate with the
number of culture passages (Figure 1), arguing against artefactual
allelic deletions during in vitro propagation. The five cell lines with
extreme high passage numbers had, in fact, FAL values below the
average FAL of 0.34 (i.e., DU4475, MCF-7, MDA-MB-435S, MDA-
MB-453, and UACC893; Figure 1). As original (preculture or
prexenograft) tumour specimens were not available for any of the
28 breast cancer samples from our cohort, we can not, however,
conclusively exclude artefactual allelic deletions. A single report
has appropriately addressed the issue of artefactual in vitro
deletions (Wistuba et al, 1998). Cell lines of 17 breast cancer
specimens had been established and the cells had been propagated
in vitro for a median period of 2 years. Comparison of 867
microsatellite analyses of the 17 cell lines to those of their
corresponding archival tumour specimens revealed an overall
concordance of 96%, indicating that allelic deletion at any time
during in vitro propagation of the breast cancer cells is negligible.
As for xenografts, studies on pancreatic cancer have shown that
allelic deletions do not occur during in vivo propagation of tumour
cells in immune-deficient mice (Caldas et al, 1994; Hahn et al,
1995). Whereas the occurrence of artefactual allelic deletions
during ex vivo propagation of cancer cells has often been
suggested, evidence for such genetic instability has, to the best of
our knowledge, never been provided. A second, more likely reason
for the higher frequencies of allelic loss in our allelotype is a more
accurate microsatellite analysis of these breast cancer samples, as
they all consist solely of neoplastic human cells. An extensive host
desmoplastic response to the tumour cells is indeed characteristic
of most breast cancers, resulting in an admixture of non-neoplastic
cells in the tumour specimens that will severely hamper genetic
analyses. Imbalances in allele quantities in microsatellite analyses
(illustrated in Figure 3) always reflect genomic amplifications
when pure tumour samples are used, such as our breast cancer cell
lines or xenografts. We observed allelic imbalances for multiple
microsatellite markers only at chromosomal arm 8q for six of the
28 breast cancer samples and at 20q for two samples, whereas
imbalances at other loci were only occasionally observed. When
primary breast cancer specimens are used, however, allelic
imbalances may also be due to residual non-neoplastic cells in
the samples, resulting in a major amplification product of the
retained allele and a minor amplification product of the lost allele.
The non-neoplastic cell content in tumour specimens may even be
as such that allelic losses go undetected. Allelic loss frequencies in
primary breast cancer specimens will therefore generally be lower
than those obtained for cell lines, xenografts, or micro-dissected
tumours. As for the five chromosomal arms that we found to be
most frequently deleted, comparable frequencies of allelic loss
(450%) in breast cancer specimens have been reported for 8p,
17p, and 17q, indicating that our allelotype indeed reflects genomic
deletions as they occur during breast tumorigenesis (Devilee et al,
1989, 1991a, 1991b; Sato et al, 1990, 1991; Cornelis et al, 1994;
Aldaz et al, 1995; Bieche and Lidereau, 1995; Fujii et al, 1996;
Kerangueven et al, 1997; Anbazhagan et al, 1998; Fukino et al,
1999; Forozan et al, 2000; Shen et al, 2000). Third, allelic losses
may be masked in karyotype-based techniques, due to genomic
amplifications or chromosomes that are aberrantly duplicated
through nondisjunction at cellular division. Indeed, two or more
copies of a chromosome have been observed in tumour
karyotypes, even though molecular analysis with polymorphic
markers had shown that those tumours had loss of heterozygosity
for that particular chromosome (Lengauer et al, 1998). As the
comparative genome hybridisation (CGH) technique does not
distinguish between paternal and maternal chromosomes, this
method is more likely to underestimate allelic loss frequencies
than microsatellite analysis. Comparison of our allelotype with
three studies that also included the ATCC breast cancer cell lines
revealed that the CGH studies had not detected one-quarter to half
of the chromosomal arms with allelic loss that we identified using
microsatellite analysis (Davidson et al, 2000; Forozan et al, 2000;
Kytola et al, 2000). Comparison of the studies is, however,
somewhat problematic. Our allelotype, for example, had not
detected about one-quarter of the losses identified by CGH,
presumably related to the limited resolution of our allelotype (one
locus per chromosomal arm). There were also differences among
the three CGH studies. Most striking was the consistent under-
estimation of the allelic losses at 17p and 17q by CGH, likely due to
several regions of amplification that are known to be present at
this chromosome, such as the ERBB2 gene at 17q12. Losses at 10q
and 13q were variably underestimated, while loss at 8p was among
the most frequent losses in all studies.
The wide range from 7% allelic loss at 1q to 82% at 17p that we
observed in our breast cancer allelotype indicated a nonrandom
deletion of genetic material, suggestive of the location of tumour
suppressor genes at the sites of frequent allelic loss. Chromosomal
arm 17p contains the p53 and MAP2K4 tumour suppressor genes
that were mutated in 20 (71%) and three (11%) of the 28 breast
cancer samples, respectively, with one tumour being double
mutant (Wasielewski and Schutte, manuscript in preparation, and
(Su et al, 2002). Together these mutation account for 88% of the
17p deletions positional candidate genes for the frequent
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Figure 2 Allelotype of 28 human breast cancer cell lines and xenografts.
Figure 3 Microsatellite analysis of marker D8S88 in breast cancer samples and non-neoplastic control samples. 1: one allele size detected; 2: two allele
sizes detected; asterix: possible allelic imbalance due to genomic amplification of the locus.
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sallelic losses at 10q, 13q, and 17q are PTEN, BRCA2 and RB1,
and BRCA1. Systematic mutational analyses of these tumour
suppressor genes in this cohort of commercially available breast
cancer samples should reveal whether these known genes indeed
were the targets of the frequent allelic losses, or that other new
tumour suppressor genes are likely to be located at these
chromosomal sites.
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